

DAFTAR PUSTAKA

1. Siddiqui F, Vaqar S, Siddiqui AH. Lung Cancer. Cambridge Handb Psychol Heal Med Second Ed [Internet]. 2022 May 5 [cited 2022 Nov 14];605–6. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK482357/>
2. What Is Cancer? - NCI [Internet]. [cited 2023 Jan 5]. Available from: <https://www.cancer.gov/about-cancer/understanding/what-is-cancer>
3. Penyakit Kanker di Indonesia Berada Pada Urutan 8 di Asia Tenggara dan Urutan 23 di Asia – P2P Kemenkes RI [Internet]. [cited 2022 Nov 14]. Available from: <http://p2p.kemkes.go.id/penyakit-kanker-di-indonesia-berada-pada-urutan-8-di-asia-tenggara-dan-urutan-23-di-asia/>
4. de Groot PM, Wu CC, Carter BW, Munden RF. The epidemiology of lung cancer. *Transl Lung Cancer Res.* 2018;7(3):220–33.
5. Arbour KC, Riely GJ. Diagnosis and Treatment of ALK Positive NSCLC. *Hematol Oncol Clin North Am* [Internet]. 2017 Feb 1 [cited 2022 Nov 14];31(1):101. Available from: [/pmc/articles/PMC5154547/](https://pubmed.ncbi.nlm.nih.gov/27154547/)
6. Du X, Shao Y, Qin H-F, Tai Y-H, Gao H-J, Yan-Hong Tai C. ALK-rearrangement in non-small-cell lung cancer(NSCLC) : ALK rearrangement in lung cancer. *Thorac Cancer.* 2018;9:423–30.
7. Solomon B, Varella-Garcia M, Camidge DR. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. *J Thorac Oncol* [Internet]. 2009 [cited 2022 Oct 24];4(12):1450–4. Available from: <https://pubmed.ncbi.nlm.nih.gov/20009909/>
8. Kempf PG, Picarsic J, Durham BH, Hélias-Rodzewicz Z, Hiemcke-Jiwa L, van den Bos C, et al. ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition. *Blood* [Internet]. 2022 Jan 13 [cited 2022 Nov 15];139(2):256–80. Available from: <https://ashpublications.org/blood/article/139/2/256/477749/ALK-positive-histiocytosis-a-new-clinicopathologic>
9. Kometani T. Clinicopathological features of younger (aged \leq 50 years) lung

- adenocarcinoma patients harboring the EML4-ALK fusion gene. 2018;9:563–70.
10. Wang H, Zhang W, Wang K, Li X. Correlation between EML4-ALK, EGFR and clinicopathological features based on IASLC/ATS/ ERS classification of lung adenocarcinoma. 2011;
 11. Heriyanto DS, Trisnawati I, Kumara EG, Laiman V, Yuliani FS, Sumpono ASB, et al. The Prevalence of the EML4-ALK Fusion Gene in Cytology Specimens from Patients with Lung Adenocarcinoma. *Pulm Med* [Internet]. 2020 [cited 2022 Nov 14];2020. Available from: <https://pubmed.ncbi.nlm.nih.gov/33425389/>
 12. Chaudhry R, Bordoni B. Anatomy, Thorax, Lungs. *StatPearls* [Internet]. 2022 Jul 25 [cited 2022 Nov 15]; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK470197/>
 13. Wicaksana A. Gray's Anatomy for Students [Internet]. <https://Medium.Com/>. 2016. Available from: <https://medium.com/@arifwicaksanaa/pengertian-use-case-a7e576e1b6bf>
 14. Hopkins E, Sharma S. Physiology, Functional Residual Capacity. *StatPearls* [Internet]. 2019 [cited 2022 Nov 15]; Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29763183>
 15. Interactions M, Metabolism C, Dynamics M, Properties N, Physiology S, Control SM, et al. *Human Physiology An Integrated Approach* (8th Edition).
 16. Ganong's Review of Medical Physiology.
 17. Brown K, Lynch DT. Histology, Lung. *StatPearls* [Internet]. 2022 May 8 [cited 2022 Nov 15]; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK534789/>
 18. Kosanke RM. *Junqueiras Basic Histology*. 2019.
 19. *Histology Of The Respiratory System Lab* [Internet]. [cited 2022 Nov 15]. Available from: http://medcell.org/tbl/histology_of_the_respiratory_system/reading.php
 20. What Is Lung Cancer? | CDC [Internet]. [cited 2022 Nov 15]. Available from: https://www.cdc.gov/cancer/lung/basic_info/what-is-lung-cancer.htm

21. Kosanke RM. Pathophysiology The Biologic Basis for Disease in Adults and Children. 2019;
22. Lung and Bronchus Cancer — Cancer Stat Facts [Internet]. [cited 2022 Nov 16]. Available from: <https://seer.cancer.gov/statfacts/html/lungb.html>
23. Yang P. Epidemiology of Lung Cancer Prognosis: Quantity and Quality of Life. *Methods Mol Biol* [Internet]. 2009 [cited 2022 Nov 17];471:469. Available from: </pmc/articles/PMC2941142/>
24. What Are the Risk Factors for Lung Cancer? | CDC [Internet]. [cited 2022 Nov 16]. Available from: https://www.cdc.gov/cancer/lung/basic_info/risk_factors.htm
25. Bade BC, Cruz CS Dela. Lung Cancer 2020 Prevention Lung cancer Tobacco smoking Epidemiology Etiology Prevention. *Clin Chest Med* [Internet]. 2020;41(1):1–24. Available from: <https://doi.org/10.1016/j.ccm.2019.10.001>
26. Phillips DH, Venitt S. DNA and protein adducts in human tissues resulting from exposure to tobacco smoke. *Int J cancer* [Internet]. 2012 Dec 15 [cited 2022 Nov 16];131(12):2733–53. Available from: <https://pubmed.ncbi.nlm.nih.gov/22961407/>
27. Health NC for CDP and HP (US) O on S and. Cancer. 2014 [cited 2022 Nov 16]; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK294309/>
28. Yang P. Lung Cancer in Never Smokers. *Semin Respir Crit Care Med* [Internet]. 2011 [cited 2022 Nov 16];32(1):10. Available from: </pmc/articles/PMC3404817/>
29. Novello S, Stabile LP, Siegfried JM. Gender-Related Differences in Lung Cancer [Internet]. Second Edi. IASLC Thoracic Oncology. Elsevier Inc.; 2018. 30-45.e5 p. Available from: <http://dx.doi.org/10.1016/B978-0-323-52357-8.00005-6>
30. Lo YL, Hsiao CF, Chang GC, Tsai YH, Huang MS, Su WC, et al. Risk factors for primary lung cancer among never smokers by gender in a matched case–control study. *Cancer Causes Control* 2012 243 [Internet]. 2012 May 22 [cited 2022 Nov 16];24(3):567–76. Available from:

<https://link.springer.com/article/10.1007/s10552-012-9994-x>

31. lung cancer indoor pollution, Zhong et al.pdf.
32. Sagerup CMT, Småstuen M, Johannesen TB, Helland Å, Brustugun OT. Sex-specific trends in lung cancer incidence and survival: A population study of 40 118 cases. *Thorax*. 2011;66(4):301–7.
33. Schwartz AG, Prysak GM, Bock CH, Cote ML. The molecular epidemiology of lung cancer. *Carcinogenesis* [Internet]. 2007 Mar [cited 2022 Nov 16];28(3):507–18. Available from: <https://pubmed.ncbi.nlm.nih.gov/17183062/>
34. El-Telbany A, Ma PC. Cancer Genes in Lung Cancer: Racial Disparities: Are There Any? *Genes Cancer* [Internet]. 2012 Jul 1 [cited 2022 Nov 16];3(7–8):467. Available from: [/pmc/articles/PMC3527990/](https://pubmed.ncbi.nlm.nih.gov/22054881/)
35. Kwak EL, Bang Y-J, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *N Engl J Med* [Internet]. 2010 Oct 28 [cited 2022 Oct 24];363(18):1693–703. Available from: <https://pubmed.ncbi.nlm.nih.gov/20979469/>
36. Larsen JE, Minna JD. Molecular biology of lung cancer: clinical implications. *Clin Chest Med* [Internet]. 2011 Dec [cited 2022 Nov 16];32(4):703–40. Available from: <https://pubmed.ncbi.nlm.nih.gov/22054881/>
37. Miller YE. Pathogenesis of lung cancer: 100 year report. *Am J Respir Cell Mol Biol* [Internet]. 2005 Sep [cited 2022 Nov 16];33(3):216–23. Available from: <https://pubmed.ncbi.nlm.nih.gov/16107574/>
38. Hashimoto A, Kawasaki Y, Tominaga A, Kakutani T, Kodama K, Nogi S, et al. Squamous Cell Lung Cancer. *JCR J Clin Rheumatol* [Internet]. 2022 Jun 19 [cited 2022 Nov 16];26(5):e137–e137. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK564510/>
39. Wicaksana A. Wickers pathology a text, atlas and review of histopathology [Internet]. <https://medium.com/>. 2016. Available from: <https://medium.com/@arifwicaksanaa/pengertian-use-case-a7e576e1b6bf>
40. Bhimji SS, Wallen JM. Lung Adenocarcinoma. *StatPearls* [Internet]. 2022 Jun 21 [cited 2022 Nov 16]; Available from:

- <https://www.ncbi.nlm.nih.gov/books/NBK519578/>
41. Basumallik N, Agarwal M. Small Cell Lung Cancer. 2022 Jul 12 [cited 2022 Nov 16]; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK482458/>
 42. American Joint Committee on Cancer | ACS [Internet]. [cited 2022 Nov 16]. Available from: <https://www.facs.org/quality-programs/cancer-programs/american-joint-committee-on-cancer/>
 43. Purandare NC, Rangarajan V. Imaging of lung cancer: Implications on staging and management. *Indian J Radiol Imaging* [Internet]. 2015 May 1 [cited 2022 Nov 16];25(2):109. Available from: </pmc/articles/PMC4419420/>
 44. Glazer HS, Duncan-Meyer J, Aronberg DJ, Moran JF, Levitt RG, Sagel SS. Pleural and chest wall invasion in bronchogenic carcinoma: CT evaluation. *Radiology* [Internet]. 1985 [cited 2022 Nov 16];157(1):191–4. Available from: <https://pubmed.ncbi.nlm.nih.gov/4034965/>
 45. Rosai and Ackerman's Surgical Pathology, 10e - 1st Edition [Internet]. [cited 2022 Oct 21]. Available from: <https://www.elsevier.com/books/rosai-and-ackermans-surgical-pathology-10e/rosai/978-81-312-2984-2>
 46. Kumar V, Abbas AK, Aster JC, Turner J. Pathologic Basis of disease tenth edition. Kumar V, K Singh M, editors. 2021;II Fig 18-23:823–79.
 47. Zheng M. Classification and Pathology of Lung Cancer. 2016 [cited 2022 Oct 21]; Available from: <http://dx.doi.org/10.1016/j.soc.2016.02.003>
 48. Pan J, Song G, Chen D, Li Y, Liu S, Hu S, et al. Identification of Serological Biomarkers for Early Diagnosis of Lung Cancer Using a Protein Array-Based Approach. *Mol Cell Proteomics* [Internet]. 2017 Dec 1 [cited 2022 Oct 21];16(12):2069. Available from: </pmc/articles/PMC5724172/>
 49. Ozaki T, Nakagawara A. Role of p53 in Cell Death and Human Cancers. *Cancers (Basel)* [Internet]. 2011 Mar [cited 2022 Oct 21];3(1):994–1013. Available from: <https://pubmed.ncbi.nlm.nih.gov/24212651/>
 50. Prior IA, Lewis PD, Mattos C. A Comprehensive Survey of Ras Mutations in Cancer. *Cancer Res* [Internet]. 2012 May 15 [cited 2022 Oct 21];72(10):2457–67. Available from:

<https://aacrjournals.org/cancerres/article/72/10/2457/575860/A-Comprehensive-Survey-of-Ras-Mutations-in>

51. Li T, Kung HJ, Mack PC, Gandara DR. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. *J Clin Oncol* [Internet]. 2013 Mar 10 [cited 2022 Oct 23];31(8):1039–49. Available from: <https://pubmed.ncbi.nlm.nih.gov/23401433/>
52. Kerr KM, Bubendorf L, Edelman MJ, Marchetti A, Mok T, Novello S, et al. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. *Ann Oncol Off J Eur Soc Med Oncol* [Internet]. 2014 [cited 2022 Oct 24];25(9):1681–90. Available from: <https://pubmed.ncbi.nlm.nih.gov/24718890/>
53. Yatabe Y, Kerr KM, Utomo A, Rajadurai P, Tran VK, Du X, et al. EGFR Mutation Testing Practices within the Asia Pacific Region: Results of a Multicenter Diagnostic Survey. *J Thorac Oncol* [Internet]. 2015 Mar 30 [cited 2022 Oct 23];10(3):438. Available from: [/pmc/articles/PMC4342317/](https://pubmed.ncbi.nlm.nih.gov/24718890/)
54. Da Cunha Santos G, Shepherd FA, Tsao MS. EGFR mutations and lung cancer. *Annu Rev Pathol* [Internet]. 2011 Feb 28 [cited 2022 Nov 16];6:49–69. Available from: <https://pubmed.ncbi.nlm.nih.gov/20887192/>
55. Sangha R, Price J, Butts CA. Adjuvant Therapy in Non-Small Cell Lung Cancer: Current and Future Directions. *Oncologist* [Internet]. 2010 Aug 1 [cited 2022 Nov 16];15(8):862. Available from: [/pmc/articles/PMC3228021/](https://pubmed.ncbi.nlm.nih.gov/20887192/)
56. Gilligan D, Nicolson M, Smith I, Groen H, Dalesio O, Goldstraw P, et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. *Lancet (London, England)* [Internet]. 2007 Jun 9 [cited 2022 Nov 17];369(9577):1929–37. Available from: <https://pubmed.ncbi.nlm.nih.gov/17544497/>
57. Postoperative radiotherapy for non-small cell lung cancer. *Cochrane database Syst Rev* [Internet]. 2005 Apr 20 [cited 2022 Nov 17];(2). Available from: <https://pubmed.ncbi.nlm.nih.gov/15846628/>
58. R A, B B, A D, T LC, JP P, J V. Cisplatin-based adjuvant chemotherapy in

- patients with completely resected non-small-cell lung cancer. *N Engl J Med* [Internet]. 2004 Jan 22 [cited 2022 Nov 17];350(4):351–60. Available from: <https://pubmed.ncbi.nlm.nih.gov/14736927/>
59. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. *BMJ* [Internet]. 1995 Oct 7 [cited 2022 Nov 17];311(7010):899–909. Available from: <https://www.bmj.com/content/311/7010/899>
60. Wisnivesky JP, Yankelevitz D, Henschke CI. Stage of lung cancer in relation to its size: part 2. Evidence. *Chest* [Internet]. 2005 [cited 2022 Nov 17];127(4):1136–9. Available from: <https://pubmed.ncbi.nlm.nih.gov/15821186/>
61. Lemjabbar-Alaoui H, Hassan OUI, Yang YW, Buchanan P. Lung cancer: biology and treatment options. *Biochim Biophys Acta* [Internet]. 2015 Dec 1 [cited 2022 Nov 17];1856(2):189. Available from: </pmc/articles/PMC4663145/>
62. Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. *J Clin Oncol* [Internet]. 2010 Feb 20 [cited 2022 Nov 17];28(6):911–7. Available from: <https://pubmed.ncbi.nlm.nih.gov/20100966/>
63. Sundstrøm S, Bremnes R, Aasebø U, Aamdal S, Hatlevoll R, Brunsvig P, et al. Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial. *J Clin Oncol* [Internet]. 2004 [cited 2022 Nov 17];22(5):801–10. Available from: <https://pubmed.ncbi.nlm.nih.gov/14990635/>
64. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. *J Clin Oncol* [Internet]. 2000 [cited 2022 Nov

- 17];18(10):2095–103. Available from:
<https://pubmed.ncbi.nlm.nih.gov/10811675/>
65. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. *Lancet Oncol* [Internet]. 2011 Oct [cited 2022 Nov 17];12(11):1004. Available from: </pmc/articles/PMC3328296/>
66. Billing PS, Miller DL, Allen MS, Deschamps C, Trastek VF, Pairolero PC. Surgical treatment of primary lung cancer with synchronous brain metastases. *J Thorac Cardiovasc Surg*. 2001;122(3):548–53.
67. Miller JI, Phillips TW. Neodymium:YAG laser and brachytherapy in the management of inoperable bronchogenic carcinoma. *Ann Thorac Surg* [Internet]. 1990 [cited 2022 Nov 17];50(2):190–6. Available from: <https://pubmed.ncbi.nlm.nih.gov/1696452/>
68. Alexander E, Moriarty TM, Davis RB, Wen PY, Fine HA, Black PM, et al. Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. *J Natl Cancer Inst* [Internet]. 1995 Jan 4 [cited 2022 Nov 17];87(1):34–40. Available from: <https://pubmed.ncbi.nlm.nih.gov/7666461/>
69. Salerno TA, Munro DD, Blundell PE, Chiu RCJ. Second primary bronchogenic carcinoma: life-table analysis of surgical treatment. *Ann Thorac Surg* [Internet]. 1979 [cited 2022 Nov 17];27(1):3–6. Available from: <https://pubmed.ncbi.nlm.nih.gov/453955/>
70. Hamaji M, Allen MS, Cassivi SD, Deschamps C, Nichols FC, Wigle DA, et al. Surgical treatment of metachronous second primary lung cancer after complete resection of non-small cell lung cancer. *J Thorac Cardiovasc Surg* [Internet]. 2013 Mar [cited 2022 Nov 17];145(3):683–91. Available from: <https://pubmed.ncbi.nlm.nih.gov/23414986/>
71. Lung Cancer Survival Rates | 5-Year Survival Rates for Lung Cancer [Internet]. [cited 2022 Nov 17]. Available from: <https://www.cancer.org/cancer/lung-cancer/detection-diagnosis->

staging/survival-rates.html

72. Toyokawa G, Seto T. Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical Data. *Oncol Res Treat* [Internet]. 2015 Jun 9 [cited 2022 Oct 24];38(6):291–8. Available from: <https://pubmed.ncbi.nlm.nih.gov/26045026/>
73. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature*. 2007;448(7153):561–6.
74. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, et al. EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer. *Clin Cancer Res* [Internet]. 2008 Jul 1 [cited 2022 Oct 24];14(13):4275–83. Available from: <https://aacrjournals.org/clincancerres/article/14/13/4275/72804/EML4-ALK-Fusion-Gene-and-Efficacy-of-an-ALK-Kinase>
75. Iyevleva AG, Raskin GA, Tiurin VI, Sokolenko AP, Mitiushkina N V., Aleksakhina SN, et al. Novel ALK fusion partners in lung cancer. *Cancer Lett* [Internet]. 2015 [cited 2022 Oct 24];362(1):116–21. Available from: <https://pubmed.ncbi.nlm.nih.gov/25813404/>
76. Uruga H, Mino-Kenudson M. ALK (D5F3) CDx: An immunohistochemistry assay to identify alk-positive NSCLC patients. *Pharmgenomics Pers Med*. 2018;11:147–55.
77. Mossé YP, Wood A, Maris JM. Inhibition of ALK signaling for cancer therapy. *Clin Cancer Res* [Internet]. 2009 Sep 15 [cited 2022 Oct 24];15(18):5609–14. Available from: <https://pubmed.ncbi.nlm.nih.gov/19737948/>
78. Mano H. Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. *Cancer Sci* [Internet]. 2008 [cited 2022 Oct 24];99(12):2349–55. Available from: <https://pubmed.ncbi.nlm.nih.gov/19032370/>
79. Selinger CI, Rogers TM, Russell PA, O’Toole S, Yip PY, Wright GM, et al. Testing for ALK rearrangement in lung adenocarcinoma: A multicenter

- comparison of immunohistochemistry and fluorescent in situ hybridization. *Mod Pathol*. 2013;26(12):1545–53.
80. Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. *Arch Pathol Lab Med* [Internet]. 2018 Mar 1 [cited 2022 Nov 17];142(3):321–46. Available from: <https://pubmed.ncbi.nlm.nih.gov/29355391/>
81. Mino-Kenudson M, Chirieac LR, Law K, Hornick JL, Lindeman N, Mark EJ, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. *Clin Cancer Res* [Internet]. 2010 Mar 1 [cited 2022 Nov 17];16(5):1561–71. Available from: <https://pubmed.ncbi.nlm.nih.gov/20179225/>
82. Ilie MI, Bence C, Hofman V, Long-Mira E, Butori C, Bouhleb L, et al. Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK 'borderline'-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies. *Ann Oncol Off J Eur Soc Med Oncol* [Internet]. 2015 Jan 1 [cited 2022 Nov 17];26(1):238–44. Available from: <https://pubmed.ncbi.nlm.nih.gov/25344360/>
83. Jokoji R, Yamasaki T, Minami S, Komuta K, Sakamaki Y, Takeuchi K, et al. Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma. *J Clin Pathol* [Internet]. 2010 Dec [cited 2022 Nov 17];63(12):1066–70. Available from: <https://pubmed.ncbi.nlm.nih.gov/20935334/>
84. Teixidó C, Karachaliou N, Peg V, Gimenez-Capitan A, Rosell R. Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements.

- Transl Lung Cancer Res [Internet]. 2014 [cited 2022 Nov 17];3(2):70. Available from: [/pmc/articles/PMC4367661/](#)
85. Arti kata usia - Kamus Besar Bahasa Indonesia (KBBI) Online [Internet]. [cited 2022 Nov 17]. Available from: <https://kbbi.web.id/usia>
 86. Sistem Informasi Rujukan Statistik - View Variabel [Internet]. [cited 2022 Nov 17]. Available from: <https://sirusa.bps.go.id/sirusa/index.php/variabel/33>
 87. Smoking | Definition, Types, Effects, History, & Facts | Britannica [Internet]. [cited 2022 Nov 17]. Available from: <https://www.britannica.com/topic/smoking-tobacco>
 88. Xie X, Li X, Tang W, Xie P, Tan X. Primary tumor location in lung cancer: the evaluation and administration. *Chin Med J (Engl)* [Internet]. 2022 Jan 1 [cited 2022 Nov 17];135(2):127. Available from: [/pmc/articles/PMC8769119/](#)
 89. Baba AI, Cătoi C. TUMOR CELL MORPHOLOGY. 2007 [cited 2022 Nov 17]; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK9553/>
 90. Holla VR, Elamin YY, Bailey AM, Johnson AM, Litzenburger BC, Khotskaya YB, et al. ALK: a tyrosine kinase target for cancer therapy. *Cold Spring Harb Mol Case Stud* [Internet]. 2017 Jan [cited 2022 Nov 17];3(1):a001115. Available from: [/pmc/articles/PMC5171696/](#)
 91. Bain C, Feskanich D, Speizer FE, Thun M, Hertzmark E, Rosner BA, et al. Lung cancer rates in men and women with comparable histories of smoking. *J Natl Cancer Inst* [Internet]. 2004 Jun 2 [cited 2023 Sep 29];96(11):826–34. Available from: <https://pubmed.ncbi.nlm.nih.gov/15173266/>
 92. Ruano-Ravina A, Provencio M, de Juan VC, Carcereny E, Estival A, Rodríguez-Abreu D, et al. Are there differences by sex in lung cancer characteristics at diagnosis? —a nationwide study. *Transl Lung Cancer Res* [Internet]. 2021 Oct 1 [cited 2023 Sep 29];10(10):3902. Available from: [/pmc/articles/PMC8577975/](#)
 93. Hong S, Fang W, Hu Z, Zhou T, Yan Y, Qin T, et al. A Large-scale Cross-sectional Study of ALK Rearrangements and EGFR Mutations in Non-small-

- cell Lung Cancer in Chinese Han Population. *Sci Reports* 2014 41 [Internet]. 2014 Dec 1 [cited 2023 Oct 1];4(1):1–8. Available from: <https://www.nature.com/articles/srep07268>
94. Yang Y, Shi C, Sun H, Yin W, Zhou X, Zhang L, et al. Elderly male smokers with right lung tumors are viable candidates for KRAS mutation screening. *Sci Rep* [Internet]. 2016 Jan 7 [cited 2023 Oct 1];6. Available from: [/pmc/articles/PMC4703983/](https://pubmed.ncbi.nlm.nih.gov/263983/)
95. Jia B, Zheng Q, Qi X, Zhao J, Wu M, An T, et al. Survival comparison of right and left side non-small cell lung cancer in stage I–IIIA patients: A Surveillance Epidemiology and End Results (SEER) analysis. *Thoracic Cancer* [Internet]. 2019 Mar 1 [cited 2023 Oct 1];10(3):459. Available from: [/pmc/articles/PMC6397910/](https://pubmed.ncbi.nlm.nih.gov/36397910/)
96. Boland JM, Erdogan S, Vasmatazis G, Yang P, Tillmans LS, Johnson MRE, et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. *Hum Pathol*. 2009 Aug 1;40(8):1152–8.
97. Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, Okui M, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. *J Thorac Oncol* [Internet]. 2008 [cited 2023 Oct 2];3(1):13–7. Available from: <https://pubmed.ncbi.nlm.nih.gov/18166835/>
98. De Paepe P, Baens M, Van Krieken H, Verhasselt B, Stul M, Simons A, et al. ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma. *Blood* [Internet]. 2003 Oct 1 [cited 2023 Oct 1];102(7):2638–41. Available from: <https://pubmed.ncbi.nlm.nih.gov/12750159/>
99. Morris SW, Naeve C, Mathew P, James PL, Kirstein MN, Cui X, et al. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). *Oncogene* [Internet]. 1997 [cited 2023 Oct 1];14(18):2175–88. Available from: <https://pubmed.ncbi.nlm.nih.gov/9174053/>